Research analysts at Svb Leerink began coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) in a report released on Friday. The brokerage set a “mkt perform” rating and a $38.00 price target on the biopharmaceutical company’s stock. Svb Leerink’s price objective indicates a potential upside of 6.95% from the stock’s previous close.

A number of other analysts have also commented on NKTR. ValuEngine lowered shares of Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, November 16th. Zacks Investment Research upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a report on Friday, November 30th. Finally, Goldman Sachs Group assumed coverage on shares of Nektar Therapeutics in a research note on Thursday, December 13th. They issued a “buy” rating and a $62.00 price target on the stock. Two analysts have rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the company. Nektar Therapeutics has a consensus rating of “Buy” and a consensus price target of $73.92.

NKTR opened at $35.53 on Friday. Nektar Therapeutics has a 1-year low of $29.22 and a 1-year high of $109.09. The company has a quick ratio of 17.39, a current ratio of 17.53 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $6.19 billion, a price-to-earnings ratio of 9.40 and a beta of 3.09.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.70) by $0.13. Nektar Therapeutics had a net margin of 57.09% and a return on equity of 50.22%. During the same quarter in the previous year, the company earned ($0.21) earnings per share. As a group, equities research analysts forecast that Nektar Therapeutics will post -3.01 EPS for the current year.

In other news, CAO Jillian B. Thomsen sold 1,808 shares of the business’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $42.39, for a total transaction of $76,641.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Howard W. Robin sold 108,882 shares of the business’s stock in a transaction dated Thursday, February 21st. The stock was sold at an average price of $42.19, for a total value of $4,593,731.58. Following the transaction, the chief executive officer now directly owns 350,924 shares of the company’s stock, valued at approximately $14,805,483.56. The disclosure for this sale can be found here. In the last three months, insiders sold 241,824 shares of company stock valued at $10,249,993. 4.31% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the business. CSat Investment Advisory L.P. raised its holdings in shares of Nektar Therapeutics by 279.2% during the fourth quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 790 shares in the last quarter. Laurel Wealth Advisors LLC purchased a new stake in shares of Nektar Therapeutics in the fourth quarter worth $39,000. Sandy Spring Bank purchased a new stake in shares of Nektar Therapeutics in the fourth quarter worth $59,000. Belpointe Asset Management LLC purchased a new stake in shares of Nektar Therapeutics in the third quarter worth $123,000. Finally, Financial Architects Inc lifted its holdings in shares of Nektar Therapeutics by 91.6% during the fourth quarter. Financial Architects Inc now owns 2,092 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 94.20% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Further Reading: What is the Book Value of a Share?

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.